Method Article

Three-Dimensional Visualization of Lymphatic Vessels in Human Skin and Their Structural Changes During Lymphedema

DOI:

10.3791/69972

February 13th, 2026

In This Article

Summary

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

Here, a three-dimensional visualization of the lymphatic vessel structure in human skin was achieved using confocal or light-sheet microscopy after the application of three distinct tissue-clearing techniques. Combinations of these methods with immunohistochemical staining provide insight into functional changes in lymphatic vessels during the progression of lymphedema.

Abstract

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

The lymphatic vessels of the skin, comprising capillaries and collecting vessels, have key roles in waste removal and immune responses, and are essential for maintaining tissue homeostasis. However, the human skin, with its three layers -- epidermis, dermis, and subcutaneous fat -- contains a dense extracellular matrix rich in collagen, so that visualizing lymphatic networks in three dimensions is challenging. To address this limitation, this paper introduces three distinct methods, each tailored to specific molecules of interest and experimental objectives, for the three-dimensional visualization of human skin lymphatics using tissue clearing reagents in combination with confocal or light-sheet microscopy. By targeting adherens junction molecules in lymphatic endothelial cells through immunohistochemistry, structural changes with clear functional implications, particularly the characteristic button-to-zipper-like remodeling of capillary junctions, were evaluated in skin tissues derived from patients with secondary lymphedema. This three-dimensional visualization technique reveals vascular structures that are not discernible through conventional histological tissue section analysis, thereby enhancing the understanding of lymphatic vessel structure and function.

Introduction

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

There is increasing interest in the function of lymphatic vessels since the recognition of their role in maintaining skin homeostasis, beyond their well-established involvement in cancer metastasis1,2. Lymphatic vessels are structurally divided into capillaries and collecting vessels, each possessing distinct characteristics. Lymphatic capillaries consist of a single-layered structure formed by lymphatic endothelial cells and serve as initial collection sites for interstitial fluid, waste products, and immune cells. In contrast, collecting lymphatic vessels have a bilayered structure with smooth muscle cells surrounding the lymphatic endothelial layer, enabling active transport of lymph fluid collected by the capillary network toward the central circulation3. Mouse models have been utilized to elucidate the structural features, particularly of bronchial lymphatic vessels, and have revealed how inflammatory conditions induce structural remodeling4. Previous work demonstrated that ultraviolet-induced inflammation causes abnormal dilation of lymphatic capillaries, which compromises their fluid collection function. The molecular mechanisms underlying this dysfunction were identified, specifically showing that increased VEGF-A expression coupled with decreased VEGF-C expression drives these structural alterations5,6,7.

While three-dimensional visualization techniques have significantly advanced understanding of the lymphatic network in mouse models8,9, comparable structural analysis of human lymphatic vessels has remained challenging. This analytical gap arises from the difficulties of working with human tissues, including limited sample availability and the technical issues involved in achieving comprehensive three-dimensional imaging. In particular, the skin, characterized by a three-layer structure comprising the epidermis, dermis, and subcutaneous fat, and functioning as a barrier to the external environment, presents greater challenges than other soft organs. Furthermore, human skin presents distinct analytical challenges relative to mouse models, including greater tissue thickness, hampering deep imaging penetration. In addition, the abundant extracellular matrix components, particularly collagen, along with their age-related structural alterations, create optical barriers that reduce the efficacy of emerging tissue-clearing techniques that have revolutionized lymphatic imaging in mice10.

Various tissue-clearing agents were previously tested to visualize human skin capillaries, demonstrating their tissue compatibility11. Following that work, tissue-clearing reagents were successfully used to visualize human skin lymphatic vessels in three dimensions12. By focusing on the adherens junctions of lymphatic endothelial cells, structural changes in lymphatic vessels associated with the progression of lymphedema were identified13. The purpose of this article is to describe in detail the procedures for three-dimensional visualization of human skin lymphatic vessels using combinations of three skin-clearing techniques, along with confocal microscopy and light-sheet microscopy, and immunohistochemical staining tailored to specific research objectives. In this study, although we focus solely on fresh human skin tissues that were fixed on the day of excision and have not undergone freeze-thaw cycles, these techniques provide insights into not only the structural changes of lymphatic vessels during disease and aging, but also the associated functional alterations.

Access restricted. Please log in or start a trial to view this content.

Protocol

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

Skin samples of human subjects were acquired from the Chiba University Hospital (Chiba, Japan). All procedures involving human subjects were approved by the Institutional Review Board of the Chiba University Hospital and the Shiseido Global Innovation Center, and all subjects provided written informed consent. The reagents and the equipment used are listed in the Table of Materials.

1. Pretreatment of human skin samples

  1. Remove the subcutaneous tissue of excised specimens upon acquisition.
    NOTE: The interval between skin excision and acquisition was approximately h. During transport, the tissue was immersed in DMEM and kept on ice packs.
  2. Place the samples with the epidermal side down on a 60 °C hot plate for 45 s to separate the epidermis and dermis.
  3. Immediately immerse the specimens in ice-cold PBS.
  4. Separate the epidermis and dermis using tweezers.
  5. Fix the dermal parts in 4% paraformaldehyde at 4°C for 16 h, and subsequently wash with PBS prior to use.
    NOTE: After fixation, the samples were stored in PBS at 4 °C, and the immunostaining steps were initiated within months.
    CAUTION PFA solution is toxic. All preparation and handling must be performed in a fume hood while wearing appropriate personal protective equipment.

2. Whole-mount immunostaining combined with clearing reagents

  1. iDISCO technique
    1. Trim the specimens to approximately 5 mm × 5 mm × 5 mm in size.
    2. Transfer the specimens into 5% Triton X-100 and 2.5% Tween 20 in PBS on an orbital shaker set to 50 rpm at 24 °C for 16 h for permeabilization.
    3. Wash the specimens with PBS at 24 °C for 1 h, repeating the process three times.
    4. Immerse the specimens in freshly prepared blocking buffer A (1% BSA, 0.1% Tween 20, 0.03% sodium azide in PBS) on an orbital shaker set to 50 rpm at 24 °C for 72 h.
    5. Incubate the specimens with primary antibody against podoplanin (1:100) in a blocking buffer A on an orbital shaker set to 50 rpm at 37 °C for 72 h.
    6. Wash the specimens with washing buffer A (0.1% Tween-20 in PBS) at 24 °C for 1 h, repeating the process three times. Then, maintain the specimens in washing buffer A on an orbital shaker set to 50 rpm at 4 °C for 72 h.
    7. Incubate the specimens with secondary antibody against mouse IgG conjugated to Alexa Fluor 647 (1:1000) in a blocking buffer A on an orbital shaker set to 50 rpm at 37 °C for 72 h.
    8. Repeat step 1.6.
    9. Incubate the specimens with 50% MeOH at 24 °C for 3 h.
    10. Incubate the specimens with 70% MeOH at 24 °C for 3 h.
    11. Incubate the specimens with 100% MeOH at 24 °C for 16 h.
    12. Incubate the specimens with dichloromethane at 24 °C for 15 min, repeating the process twice.
    13. Clear the specimens with dibenzyl ether at 24 °C for 16 h.
      NOTE: If the tissue has not become transparent at this point, further waiting will result in no significant improvement.
    14. Capture images of the specimens with a light-sheet microscope.
      NOTE: Use a Lightsheet with an EC Plan-Neofluar 5×/0.16 objective; set illumination (excitation) at 63 nm and detection at 648 nm; acquire a Z-stack with a step size of 5.8 µm.
      CAUTION: Methanol, dichloromethane, and dibenzyl ether are hazardous. All preparation and handling must be performed in a fume hood while wearing appropriate personal protective equipment.
  2. Rapiclear 1.52 reagent
    1. Trim the specimens to approximately 5 mm × 5 mm × 2 mm in size.
    2. Transfer the specimens into 2% Triton-X 100 in PBS on an orbital shaker set to 50 rpm at 24 °C for 16 h for permeabilization.
    3. Immerse the specimens in freshly prepared blocking buffer B (5% donkey serum and 1% Triton-X 100 in PBS) on an orbital shaker set to 50 rpm at 4 °C for 16 h.
    4. Incubate the specimens with primary antibodies against podoplanin and VE-cadherin (both at 1:100) in a blocking buffer B on an orbital shaker set to 50 rpm at 4 °C for 72 h.
    5. Wash the specimens with washing buffer B (3% NaCl and 0.2% Triton-X 100 in PBS) at 24 °C for 1 h, repeating the process three times. Then, maintain the specimens in washing buffer B on an orbital shaker set to 50 rpm at 4 °C for 16 h.
    6. Wash the specimens with PBS at 24 °C for 1 h.
    7. Incubate the specimens with secondary antibodies against mouse IgG and rabbit IgG, conjugated to Alexa Fluor 647 and 568, respectively (both at 1:1000), in blocking buffer B on an orbital shaker set to 50 rpm at 4 °C for 16 h.
    8. Repeat steps 1.5. and 1.6.
    9. Clear the specimens with at least 5 times the sample volume of Rapiclear 1.52 at 24 °C for 16 h.
      NOTE: The clearing of the peripheral regions of the tissue was observed in less than 1 h.
    10. Embed the cleared specimens in a polydimethylsiloxane gel chamber placed on a coverslip with fresh Rapiclear 1.52 reagent.
    11. Image the specimens with a confocal microscope.
      NOTE: Use a confocal microscope with a Plan-Apochromat 10×/0.45 M27 objective; set excitation at 633 nm and 561 nm, and detection range 641-754 nm and 566-628 nm, with a GaAsP detector; acquire a Z-stack with a step size of 3.15 µm.
  3. CUBIC technique
    1. Trim the specimens to approximately 5 mm × 5 mm × 3 mm in size.
    2. Immerse the specimens in 50% CUBIC-L at 24 °C for 24 h as a pretreatment for delipidation.
    3. Transfer the specimens into 100% CUBIC-L on an orbital shaker set to 50 rpm at 37 °C for 7 days for delipidation.
    4. Wash the specimens with PBS at room temperature for 24 h.
    5. Immerse the specimens in freshly prepared blocking buffer A on an orbital shaker set to 50 rpm at 24 °C for 72 h.
    6. Incubate the specimens with primary antibody against VE-cadherin, podoplanin, and CD31 (1:100, 1:100, and 1:200, respectively) in blocking buffer A on an orbital shaker set to 50 rpm at 37 °C for 72 h.
    7. Wash the specimens with washing buffer A at 24 °C for 1 h. Repeat the process three times, then maintain the specimens in washing buffer A on an orbital shaker set to 50 rpm at 4 °C for 72 h.
    8. Incubate the specimens with secondary antibodies against mouse IgG, rabbit IgG, and sheep IgG, conjugated to Alexa Fluor 647, 568, and 488, respectively (all at 1:1000), in blocking buffer A on an orbital shaker set to 50 rpm at 37 °C for 72 h.
    9. Repeat step 3.7.
    10. Pre-clear the specimens with 50% CUBIC-R+(M) at 24 °C for 16 h.
    11. Clear the specimens with 100% CUBIC-R+(M) at 24 °C for 16 h.
      NOTE: If the tissue has not become transparent at this point, further waiting will result in no significant improvement.
    12. Image the specimens with a confocal microscope.
      ​NOTE: Use a confocal microscope with a Plan-Apochromat 20×/0.8 M27 objective; set excitation at 633 nm, 561 nm, and 488 nm, and detection range 641-754 nm, 566-628 nm, and 479-550 nm, with a GaAsP detector; acquire a Z-stack with a step size of 0.78 µm.

Access restricted. Please log in or start a trial to view this content.

Results

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

Difference in light transmittance of cleared human skin tissue with and without epidermis
Figure 1 shows representative photographs of human skin specimens with and without epidermis, following permeabilization and clearing with Rapiclear 1.52 reagent. Epidermal removal enhances tissue transparency by eliminating melanin, a potent light absorber, as confirmed by the enhanced visibility of the black line beneath the samples.

Three-dimen...

Access restricted. Please log in or start a trial to view this content.

Discussion

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

Three-dimensional visualization of lymphatic networks in biological tissues is critically important for understanding their structural characteristics and physiological functions, as well as pathological changes. This protocol presents three distinct tissue clearing methods optimized for human skin tissue, each tailored for specific observational objectives.

Epidermal removal is considered a critical step for eliminating melanin, which reduces tissue transparency and interferes with histologic...

Access restricted. Please log in or start a trial to view this content.

Disclosures

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

K.T., E.G., N.I., and K.K. are employees of Shiseido Co., Ltd.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
Anti-CD31 antibodyR&D SystemsAF806dilution at 1:200
Anti-Podoplanin antibodyDakoM3619dilution at 1:100
Anti-VE-cadherin antibodyCell Signaling Technology#2500dilution at 1:100
CUBIC-LTokyo Chemical IndustryT3740
CUBIC-R+(M)Tokyo Chemical IndustryT3741
DMEM, low glucose, pyruvateThermo Fisher SCIENTIFIC11885084
Donkey anti-Mouse IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 647Thermo Fisher SCIENTIFICA-31571dilution at 1:1000
Donkey anti-Rabbit IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 568Thermo Fisher SCIENTIFICA10042dilution at 1:1000
Donkey anti-Sheep IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 488Thermo Fisher SCIENTIFICA-11015dilution at 1:1000
Rapiclear 1.52Sunjin LabRC152001
ZEISS Lightsheet Z.1 MicroscopeCarl Zeiss
ZEISS LSM 880 Confocal Laser Scanning MicroscopeCarl Zeiss

References

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,
  1. Skobe, M., Detmar, M. Structure, function, and molecular control of the skin lymphatic system. J Investig Dermatol Symp Proc. 5 (1), 14-19 (2000).
  2. Yang, Y., Wang, X., Wang, P. Signaling mechanisms underlying lymphatic vessel dysfunction in skin aging and possible anti-aging strategies. Biogerontology. 24 (5), 727-740 (2023).
  3. Oliver, G., Kipnis, J., Randolph, G. J., Harvey, N. L. The Lymphatic Vasculature in the 21st Century: Novel Functional Roles in Homeostasis and Disease. Cell. 182 (2), 270-296 (2020).
  4. Baluk, P., McDonald, D. M. Imaging Lymphatics in Mouse Lungs. Methods Mol Biol. 1846, 161-180 (2018).
  5. Kajiya, K., Hirakawa, S., Detmar, M. Vascular endothelial growth factor-A mediates ultraviolet B-induced impairment of lymphatic vessel function. Am J Pathol. 169 (4), 1496-1503 (2006).
  6. Kajiya, K., Detmar, M. An important role of lymphatic vessels in the control of UVB-induced edema formation and inflammation. J Invest Dermatol. 126 (4), 919-921 (2006).
  7. Sawane, M., Kidoya, H., Muramatsu, F., Takakura, N., Kajiya, K. Apelin attenuates UVB-induced edema and inflammation by promoting vessel function. Am J Pathol. 179 (6), 2691-2697 (2011).
  8. Kirschnick, N., et al. Rapid methods for the evaluation of fluorescent reporters in tissue clearing and the segmentation of large vascular structures. iScience. 24 (6), 102650(2021).
  9. Orlich, M., Kiefer, F. A qualitative comparison of ten tissue clearing techniques. Histol Histopathol. 33 (2), 181-199 (2017).
  10. Tainaka, K., et al. Whole-body imaging with single-cell resolution by tissue decolorization. Cell. 159 (4), 911-924 (2014).
  11. Kajiya, K., Bise, R., Commerford, C., Sato, I., Yamashita, T., Detmar, M. Light-sheet microscopy reveals site-specific 3D patterns of the cutaneous vasculature and pronounced rarefication in aged skin. J Dermatol Sci. 92 (1), 3-5 (2018).
  12. Sawane, M., et al. Apelin provides an alternative function to estrogen in regulating lymphatic vascular integrity. J Dermatol Sci. 111 (3), 124-127 (2023).
  13. Itai, N., et al. Lymphangiogenesis and lymphatic zippering in skin associated with the progression of lymphedema. J Invest Dermatol. 144 (3), 659-668.e7 (2024).
  14. Breiteneder-Geleff, S., et al. Podoplanin-a specific marker for lymphatic endothelium expressed in angiosarcoma. Verh Dtsch Ges Pathol. 83, 270-275 (1999).
  15. Suami, H., Scaglioni, M. F. Anatomy of the lymphatic system and the lymphosome concept with reference to lymphedema. Semin Plast Surg. 32 (1), 5-11 (2018).
  16. Avraham, T., et al. Fibrosis is a key inhibitor of lymphatic regeneration. Plast Reconstr Surg. 124 (2), 438-450 (2009).
  17. Giannotta, M., Trani, M., Dejana, E. VE-cadherin and endothelial adherens junctions: active guardians of vascular integrity. Dev Cell. 26 (5), 441-454 (2013).
  18. Newman, P. J., et al. PECAM-1 (CD31): cloning and relation to adhesion molecules of the immunoglobulin gene superfamily. Science. 247 (4947), 1219-1222 (1990).
  19. Bhutto, I. A., et al. Visualization of choroidal vasculature in pigmented mouse eyes from experimental models of AMD. Exp Eye Res. 238, 109741(2024).
  20. Cichoń, M. A., Elbe-Bürger, A. Epidermal/Dermal separation techniques and analysis of cell populations in human skin sheets. J Invest Dermatol. 143 (1), 11-17.e8 (2023).
  21. Takahashi, K., et al. An analysis modality for vascular structures combining tissue-clearing technology and topological data analysis. Nat Commun. 13 (1), 5239(2022).
  22. Susaki, E. A., et al. Advanced CUBIC protocols for whole-brain and whole-body clearing and imaging. Nat Protoc. 10 (11), 1709-1727 (2015).
  23. Susaki, E. A., et al. Whole-brain imaging with single-cell resolution using chemical cocktails and computational analysis. Cell. 157 (3), 726-739 (2014).
  24. Tainaka, K., et al. Chemical landscape for tissue clearing based on hydrophilic reagents. Cell Rep. 24 (8), 2196-2210.e9 (2018).
  25. Banerji, S., et al. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol. 144 (4), 789-801 (1999).
  26. Wigle, J. T., Oliver, G. Prox1 function is required for the development of the murine lymphatic system. Cell. 98 (6), 769-778 (1999).
  27. Johnson, L. A., et al. Inflammation-induced uptake and degradation of the lymphatic endothelial hyaluronan receptor LYVE-1. J Biol Chem. 282 (46), 33671-33680 (2007).
  28. Pechtimaldjian, L., et al. Skin-iDISCO+: An optimized tissue-clearing and labeling protocol for morphometric analysis of human cutaneous vasculature. STAR Protoc. 6 (1), 103524(2024).
  29. Hägerling, R., et al. VIPAR, a quantitative approach to 3D histopathology applied to lymphatic malformations. JCI Insight. 2 (16), e93424(2017).

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Request permission to reuse the text or figures of this JoVE article

Request Permission

Tags

Lymphatic VesselsHuman SkinThree Dimensional VisualizationLymphedemaTissue ClearingConfocal MicroscopyLight Sheet MicroscopyImmunohistochemistryCapillary JunctionsLymphatic Endothelial Cells

Related Articles